journal article·2019-07

A computational study of the dual effect of intermittent and continuous administration of parathyroid hormone on bone remodeling

Yu Zhao, Guigen Zhang

Acta Biomaterialia· Volume 93
Publisher page

Abstract

Bone remodeling is a process known to be governed by constant interactions between osteoblast and osteoclast through complex pathway networks mediated by signaling factors. Experimental studies show that intermittent and continuous administration of PTH/PTHrP led to opposite outcomes in terms of bone mass. To investigate this dual effect of PTH/PTHrP, we develop a computational model based on a simplified signaling pathway network which includes relevant molecular effectors and cells. Multiple ordinary differential equations linking all considered components in the signaling pathway network through reaction kinetics are solved with dose values and patterns of injection from experiments as input. Modeling results show good agreement with experimental observations in that continuous injection of PTH/PTHrP generates catabolic effect on bone mass while intermittent injection yields anabolic effect. The signaling factors governing the interaction between osteoblast and osteoclast indeed play a key role in the dual effect of PTH/PTHrP. Furthermore, there appears to be an optimal interval for intermittent injection of PTH/PTHrP for yielding the most bone regeneration, and a synergistic outcome could be achieved by combining intermittent injection of PTH/PTHrP with application of a treatment (to mimic the filling of bone defects with polymeric scaffolds). This modeling work sheds valuable insights into the influence of temporal control of PTH/PTHrP on bone mass and presents a possible path toward bridging bioengineering approaches with clinical treatment strategies. STATEMENT OF SIGNIFICANCE: A computational model considering simplified signaling pathways containing crucial components of PTH, PTHrP, osteoblast precursor, osteoblast, osteoclast precursor, osteoclast, RANKL and IL-6 family cytokoines has been developed to study the dual effect of PTH/PTHrP on bone metabolism. The model takes the dose values and patterns of injection from experiments as input and yields predictions that convincingly match experimental measurements. This work highlights the importance of providing an optimal hormone treatment strategy for maintaining healthy bone metabolism. Moreover, the integrative approach of relying on experimental observations to find reasonable values for relevant modeling parameters has been proven to be powerful in advancing our understanding of biological interactions among cells and signaling factors.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Bone health and treatments · Bone Metabolism and Diseases · Bone health and osteoporosis research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Mechanical strain and bone cell function: a review10.1007/s001980200095 ↗
2. Growth hormone, insulin-like growth factors, and the skeleton10.1210/er.2007-0036 ↗
3. Circulating levels of IGF-1 directly regulate bone growth and density10.1172/JCI0215463 ↗
4. Transforming growth factor-beta and remodeling of bone10.2106/00004623-199173090-00022 ↗
5. TGF-β and BMP signaling in osteoblast differentiation and bone formation10.7150/ijbs.2929 ↗
6. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH10.1016/j.bone.2007.03.017 ↗
7. Endogenous tissue engineering: PTH therapy for skeletal repair10.1007/s00441-011-1188-4 ↗
8. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide10.1126/science.1658941 ↗
9. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone10.1172/JCI6610 ↗
10. Intermittent parathyroid hormone treatment enhances guided bone regeneration in rat calvarial bone defects10.1097/00001665-200405000-00014 ↗
11. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use10.1210/er.2004-0006 ↗
12. Mechanisms of anabolic therapies for osteoporosis10.1056/NEJMra067395 ↗
13. Effect of systemic parathyroid hormone (1–34) and a β-tricalcium phosphate biomaterial on local bone formation in a critical-size rat calvarial defect model10.1111/j.1600-051X.2010.01547.x ↗
14. PTH promotes allograft integration in a calvarial bone defect10.1021/mp400292p ↗
15. Local pulsatile PTH delivery regenerates bone defects via enhanced bone remodeling in a cell-free scaffold10.1016/j.biomaterials.2016.10.049 ↗
16. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone10.1002/jbmr.5650070110 ↗
17. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells10.1210/endo.136.8.7628403 ↗
18. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1–34) on rat bone
19. Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling10.1016/S8756-3282(03)00157-1 ↗
20. Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone10.1210/en.2004-1642 ↗
21. Mathematical modeling of spatio-temporal dynamics of a single bone multicellular unit10.1359/jbmr.081229 ↗
22. The cellular dynamics of bone remodeling: a mathematical model10.1137/090746094 ↗
23. Parathyroid hormone temporal effects on bone formation and resorption10.1006/bulm.1999.0146 ↗
24. Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy10.1016/S0303-2647(03)00040-6 ↗
25. Model structure and control of bone remodeling: a theoretical study10.1016/j.bone.2008.03.025 ↗
26. Regulation of bone remodeling by the central and peripheral nervous system10.1016/j.abb.2008.03.016 ↗
27. Vasodilation to PTH (1–84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling10.1016/j.bone.2013.01.028 ↗
28. Intermittent PTH (1–84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites10.1002/jbmr.459 ↗
29. PTH-enhanced structural allograft healing is associated with decreased angiopoietin-2–mediated arteriogenesis, mast cell accumulation, and fibrosis10.1002/jbmr.1765 ↗
30. Teriparatide treatment improves bone defect healing via anabolic effects on new bone formation and non-anabolic effects on inhibition of mast cells in a murine cranial window model10.1002/jbmr.3178 ↗
31. Teriparatide attenuates scarring around murine cranial bone allograft via modulation of angiogenesis10.1016/j.bone.2017.01.020 ↗
32. Vitamin D status affects serum parathyroid hormone concentrations during winter in female adolescents: associations with forearm bone mineral density10.1093/ajcn/74.2.206 ↗
33. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation10.1182/blood.V83.9.2731.2731 ↗
34. Characterization of stromal progenitor cells enriched by flow cytometry10.1182/blood.V90.9.3471 ↗
35. Synthetic peptides comprising the amino-terminal sequence of a parathyroid hormone-like protein from human malignancies. Binding to parathyroid hormone receptors and activation of adenylate cyclase in bone cells and kidney10.1016/S0021-9258(18)37641-5 ↗
36. Parathyroid hormone-like proteins: biochemical responses and receptor interactions10.1210/edrv-10-4-476 ↗
37. Parathyroid hormone (PTH)/PTH-related peptide receptor density modulates activation of phospholipase C and phosphate transport by PTH in LLC-PK1 cells10.1210/endo.136.9.7649096 ↗
38. Inactivation of pertussis toxin-sensitive guanyl nucleotide-binding proteins increase parathyroid hormone receptors and reverse agonist-induced receptor down-regulation in ROS 17/2.8 cells10.1210/endo-125-5-2594 ↗
39. Characterization and agonist-induced down-regulation of parathyroid hormone receptors in clonal rat osteosarcoma cells10.1210/endo-122-4-1208 ↗
40. Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1–34)[PTH-(1–34)] and PTH-related peptide-(1–34) in healthy young humans
41. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1–34): kinetics and biochemical response in estrogenized osteoporotic patients
42. Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity10.1016/j.ejphar.2006.09.007 ↗
43. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer10.1210/jcem-73-6-1309 ↗
44. Anabolic effect of high doses of human parathyroid hormone (1–38) in mature intact female rats10.1002/jbmr.5650090619 ↗
45. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone10.1002/jcb.10490 ↗
46. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration10.1210/endo-110-2-506 ↗